News

Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference
Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and ...
ADAR1 Capital Management urges Keros Therapeutics for board change
ADAR1 Capital Management challenges Keros Therapeutics on capital allocation and board decisions. Read more here.
Keros Therapeutics' (NASDAQ:KROS) Earnings May Just Be The Starting Point
Investors were underwhelmed by the solid earnings posted by Keros Therapeutics, Inc. ( NASDAQ:KROS ) recently. We ...
Keros Therapeutics Shareholder ADAR1 Capital to Withhold Votes for Two Board Members
Keros Therapeutics shareholder ADAR1 Capital Management said it plans to withhold votes for board members Mary Ann Gray and Alpna Seth.
Keros Therapeutics, Inc.: Keros Reinforces Commitment to Maximizing Stockholder Value
Responds to Recent Public Stockholder Communications Urges Stockholders to Protect Their Investment by Voting "FOR" the Company's Highly Qualified Director Nominees LEXINGTON, Mass., May 08, 2025 ...
Nasdaq6d
Keros Therapeutics Urges Stockholders to Support Board Nominees Amid ADAR1 Capital Management's Recent Communications
Keros Therapeutics, Inc. issued a statement addressing misleading claims made by ADAR1 Capital Management ahead of its upcoming 2025 Annual Meeting of Stockholders on June 4, 2025. Keros' Board is ...
The Globe and Mail5d
Keros Therapeutics Reports Recent First Quarter 2025 Financial Results
LEXINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical ...
Yahoo Finance6d
Keros Reinforces Commitment to Maximizing Stockholder Value
LEXINGTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”, the “Company” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and ...